Radiopharmeaceuticals

Radiopharmaceuticals are drugs that contain radioactive materials, known as radioisotopes. These drugs may be administered by multiple routes and travel to the body to treat cancer or to reduce symptoms. Radiopharmaceuticals release radiation (alpha and beta particles) that target the affected areas.
 
Everyone responds to radiopharmaceuticals differently. Talk to your doctor or pharmacist about what to expect, including any side-effects you may experience while on these medications. Some therapies used to treat prostate cancer may interact with other prescription or non-prescription medications you are taking. Tell your doctor or pharmacist if you are taking any medications.
 
Below is a list of common radiopharmaceuticals used to treat prostate cancer. Click on each drug name for further information including:
 
  • what the drug is and how it works
  • how the drug is administered
  • possible side effects of the drug
  • whether the drug is covered by your provincial drug program

Radium 223 Dichloride (Xofigo)
 




 



Plaid for Dad


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Honouring dad this Father’s Day the Canadian way: In plaid

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer.
More

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.
More

Landmark study links tumour evolution to prostate cancer severity

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved.
More


Click here for news archive